Stand Up To Cancer的动态

Discover the simplicity of seamless lab integration with CoreBioLabs – Your partner in advancing healthcare diagnostics. Learn more at

Spacing Out Cosentyx and Vaccine: A Guide for Patients and Healthcare Professionals Introduction Cosentyx,... https://lnkd.in/emtTU_Ht

Top 5 Leading Companies in PCR for Point-of-Care Diagnostics! ??? Curious about who’s making waves in the world of #PCRtechnology for point-of-care diagnostics? Dive into our #latestblog to discover the top 5 companies revolutionizing #healthcare with cutting-edge PCR solutions. From rapid test #innovations to game-changing technologies, these industry leaders are at the forefront of transforming patient care! Don't miss out on the latest advancements that are shaping the future of #medicaldiagnostics. Read the full #blog now and stay ahead of the curve! ???? https://bit.ly/46sMagq #MarketTrends #MarketGrowth #MarketResearch #PCR #HealthcareInnovation #PointOfCareDiagnostics #MedicalTech #FutureOfMedicine #DiagnosticExcellence

AstraZeneca has posted details for a Phase 1/2 study designed to evaluate if AZD5492, a CD20×TCR×CD8 tri-specific antibody, is safe, tolerable and efficacious in participants with relapsed or refractory B-cell malignancies. The study will enroll an estimated 174 patients and has an estimated start date in late Aug 2024. https://lnkd.in/edUBx24a AZD5492 is an asymmetric, trispecific monoclonal IgG1 antibody that harbors two Fab binding domains to CD20, one VHH binding domain to TCR, one VHH binding domain to CD8 co-receptor. https://lnkd.in/esbvU7xU

Please see below for how LabConnect can enhance your clinical trials!

No matter the size or complexity of your clinical trial, LabConnect can help get your samples where they need to be.

Sharing the latest blog from my team at LabConnect! Is your central lab partner delivering across these 7 areas?

#LabConnect #GlobalCentralLab #CentralLab #FSPSolutions For sponsors and CROs, reducing time-to-market and improving patient access to innovative treatments remain pressing challenges and top priorities. That is why they must partner with a central lab with a global presence. Check out our latest blog where we dive into the top 7 considerations when choosing a central lab partner ?? https://lnkd.in/eczfSX5c

In more clinical trials news, Oruka Therapeutics has queued a first-in-human, single ascending dose study evaluating the safety, tolerability, and pharmacokinetics of ORKA-001 in healthy volunteers. ORKA-001 is a novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19.?ORKA-001 has the potential to be dosed just once or twice a year and is designed to achieve higher exposures than currently marketed IL-23p19 antibodies. Due to start in March 2025, the study will recruit an estimated 24 patients. #mabs https://lnkd.in/d28_sfmt

Meet Nicoya’s Alto? – the world's most user-friendly SPR system for vaccine research. Traditional binding analysis in vaccine discovery often requires: ?? 90+ minutes of hands-on time ?? 200+ μL of sample ?? Specialized expertise With Alto: ? Only 2 μL of sample needed ?? <30 minutes of hands-on time ?? Automated assays simplify your workflows Why Choose Alto? - Sample-friendly: Compatible with crude samples and serum, low sample volumes - User-friendly: Pre-defined protocols, one-click analysis for titer, screening, epitope binning, kinetics, and potency measurements - Budget-friendly: Affordable upfront and maintenance costs Viruses evolve. So should your research tools. ?? Discover the power of Alto digital SPR today and accelerate your vaccine discovery and characterization! Reach out to us at [email protected] or 77188 10037. https://lnkd.in/geB37fCM #VaccineResearch #DigitalSPR #BiomolecularInteraction #DrugDiscovery #LabAutomation #medispec #surfaceplasmonresonance